The Correlation between Estimated Glomerular Filtration Rate and Parathyroid Hormone Levels in Predialysis-chronic Kidney Disease Adult Patients at Sanglah General Hospital, Bali, Indonesia

Sianny Herawati; Yenny Kandarini; I Putu Yuda Prabawa

doi:10.3889/oamjms.2021.6097

Authors

Sianny Herawati Department of Clinical Pathology, Faculty of Medicine, Universitas Udayana, Sanglah General Hospital, Bali, Indonesia
Yenny Kandarini Department of Internal Medicine, Faculty of Medicine, Universitas Udayana, Sanglah General Hospital, Bali, Indonesia
I Putu Yuda Prabawa Department of Clinical Pathology, Faculty of Medicine, Universitas Udayana, Sanglah General Hospital, Bali, Indonesia

DOI:

https://doi.org/10.3889/oamjms.2021.6097

Keywords:

Chronic kidney disease, Parathyroid hormone, Glomerular filtration rate

Abstract

BACKGROUND: Chronic kidney disease (CKD) is a structural or functional kidney disease for more than 3 months. In predialysis CKD patients, the serum parathyroid hormone levels increase progressively since the early stages of the disease to maintain phosphate homeostasis. Glomerular filtration rate (GFR) has been widely accepted to assess renal function. The GFR assessment is used to determine the CKD stadium.

AIM: This study aims to analyze the correlation between GFR and parathyroid hormone levels in predialysis CKD patients undergoing treatment at Sanglah General Hospital Denpasar.

METHODS: A cross-sectional observational study was conducted among predialysis CKD patients undergoing treatment at Sanglah General Hospital Denpasar who met the inclusion and exclusion criteria. The inclusion criteria were adult patients (≥18 years) who were accepting to participate in the study. Exclusion criteria were patients with predialysis CKD after thyroidectomy and/or parathyroidectomy and liver disease. The parathyroid hormone levels, blood urea nitrogen, creatinine, and GFR were examined and analyzed by SPSS version 17 for Windows.

RESULTS: A total of 77 patients with predialysis CKD in this study obtained a median of e-GFR of 21.09 (4.72–75.80) mL/min/1.73 m². The median level of parathyroid hormone was 82.07 pg/mL (15.83–716.60 pg/mL). Spearman’s correlation analysis results obtained a strong and significant negative correlation between the e-GFR value and parathyroid hormone levels (r = −0.540; p = 0.000).

CONCLUSION: The parathyroid hormone levels assessment could be used as a recommendation in evaluating the CKD progressivity among predialysis adult patients at Sanglah General Hospital, Bali, Indonesia, due to the strong significant correlation.

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

Plum Analytics Artifact Widget Block

References

Webster AC, Nagler EV, Morton RL, Masson P. Chronic kidney disease. Lancet. 2017;389(10075):1238-52. https://doi.org/10.1016/s0140-6736(16)32064-5 PMid:27887750 DOI: https://doi.org/10.1016/S0140-6736(16)32064-5

Hill NR, Fatoba ST, Oke JL, Hirst JA, O’Callaghan CA, Lasserson DS, et al. Global prevalence of chronic kidney disease-a systematic review and meta-analysis. PLoS One. 2016;11(7):e0158765. https://doi.org/10.1371/journal.pone.0158765 PMid:27383068 DOI: https://doi.org/10.1371/journal.pone.0158765

Banerjee D, Jha V. Vitamin D and cardiovascular complications of CKD: What’s next? Clin J Am Soc Nephrol. 2019;14(6):932-4. PMid:31064752 DOI: https://doi.org/10.2215/CJN.12581018

Neuen BL, Chadban SJ, Demaio AR, Johnson DW, Perkovic V. Chronic kidney disease and the global NCDs agenda. BMJ Glob Health. 2017;2(2):e000380. https://doi.org/10.1136/bmjgh-2017-000380 PMid:29225940 DOI: https://doi.org/10.1136/bmjgh-2017-000380

Indonesia Ministry of Health. National Ministry of Health Reports 2018. Jakarta: National Institute of Health Research and Development; 2018. https://doi.org/10.25133/jpssv27n1.003 DOI: https://doi.org/10.25133/JPSSv27n1.003

Sanglah General Hospital, Outpatient Installation Service Report for at Sanglah Hospital Denpasar During May 2019; 2019.

Kanai G, Fukagawa M. CKD-MBD (chronic kidney disease-mineral and bone disorder). Gene therapy for secondary hyperparathyroidism. Clin Calcium. 2010;20(7):1052-9. PMid:20585184

Wei Y, Lin J, Yang F, Li X, Hou Y, Lu R, et al. Risk factors associated with secondary hyperparathyroidism in patients with chronic kidney disease. Exp Ther Med. 2016;12(2):1206-12. PMid:27446345 DOI: https://doi.org/10.3892/etm.2016.3438

Yuen NK, Ananthakrishnan S, Campbell MJ. Hyperparathyroidism of renal disease. Perm J. 2016;20(3):15-127. PMid:27479950

Bello AK, Alrukhaimi M, Ashuntantang GE, Basnet S, Rotter RC, Douthat WG, et al. Complications of chronic kidney disease: Current state, knowledge gaps, and strategy for action. Kidney Int Suppl (2011). 2017;7(2):122-9. https://doi.org/10.1016/j.kisu.2017.07.007 PMid:30675426 DOI: https://doi.org/10.1016/j.kisu.2017.07.007

Coen G, Ballanti P, Bonucci E, Calabria S, Costantini S, Ferrannini M, et al. Renal osteodystrophy in predialysis and hemodialysis patients: Comparison of histologic patterns and diagnostic predictivity of intact PTH. Nephron. 2002;91(1):103-11. https://doi.org/10.1159/000057611 PMid:12021526 DOI: https://doi.org/10.1159/000057611

Borrelli S, Chiodini P, de Nicola L, Minutolo R, Provenzano M, Garofalo C, et al. Prognosis and determinants of serum PTH changes over time in 1-5 CKD stage patients followed in tertiary care. PLoS One. 2018;13(8):e0202417. https://doi.org/10.1371/journal.pone.0202417 PMid:30138402 DOI: https://doi.org/10.1371/journal.pone.0202417

de Boer IH, Gorodetskaya I, Young B, Hsu CY, Chertow GM. The severity of secondary hyperparathyroidism in chronic renal insufficiency is GFR-dependent, race-dependent, and associated with cardiovascular disease. J Am Soc Nephrol. 2002;13(11):2762-9. https://doi.org/10.1097/01.asn.0000034202.91413.eb PMid:12397047 DOI: https://doi.org/10.1097/01.ASN.0000034202.91413.EB

Erratum: Kidney disease: Improving global outcomes (KDIGO) CKD-MBD update work group. KDIGO 2017 clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int Suppl. 2017;7:1-59. Kidney Int Suppl (2011). 2017;7(3):e1. https://doi.org/10.1016/j.kisu.2017.10.001 PMid:30681074 DOI: https://doi.org/10.1016/j.kisu.2017.10.001

Kakuta T, Ishida M, Fukagawa M. Critical governance issue of parathyroid hormone assays and its selection in the management of chronic kidney disease mineral and bone disorders. Ther Apher Dial. 2018;22(3):220-8. https://doi.org/10.1111/1744-9987.12690 PMid:29781225 DOI: https://doi.org/10.1111/1744-9987.12690

Chen TK, Knicely DH, Grams ME. Chronic kidney disease diagnosis and management: A review. JAMA. 2019;322(13):1294- 304. https://doi.org/10.1001/jama.2019.14745 PMid:31573641 DOI: https://doi.org/10.1001/jama.2019.14745

Delanaye P, Cavalier E. Staging chronic kidney disease and estimating glomerular filtration rate: An opinion paper about the new international recommendations. Clin Chem Lab Med. 2013;51(10):1911-7. https://doi.org/10.1515/cclm-2013-0223 PMid:23729625 DOI: https://doi.org/10.1515/cclm-2013-0223

Stavroulopoulos A, Porter CJ, Roe SD, Hosking DJ, Cassidy MJ. Relationship between Vitamin D status, parathyroid hormone levels and bone mineral density in patients with chronic kidney disease stages 3 and 4. Nephrology (Carlton). 2008;13(1):63-7. https://doi.org/10.1111/j.1440-1797.2007.00860.x PMid:18199106 DOI: https://doi.org/10.1111/j.1440-1797.2007.00860.x

Wang WH, Chen LW, Lee CC, Sun CY, Shyu YC, Hsu HR, et al. Association between parathyroid hormone, 25 (OH) Vitamin D, and chronic kidney disease: A population-based study. Biomed Res Int. 2017;2017:7435657. https://doi.org/10.1155/2017/7435657 PMid:28367447 DOI: https://doi.org/10.1155/2017/7435657

Muntner P, Jones TM, Hyre AD, Melamed ML, Alper A, Raggi P, et al. Association of serum intact parathyroid hormone with lower estimated glomerular filtration rate. Clin J Am Soc Nephrol. 2009;4(1):186-94. https://doi.org/10.2215/cjn.03050608 PMid:19019998 DOI: https://doi.org/10.2215/CJN.03050608

Pala AS, Kaya E, Alagoz S, Trabulus S, Bolayirli M, Altiparmak MR, et al. Prevalence of Vitamin D deficiency in patients with stage 3/4 chronic kidney disease and its relation to secondary hyperparathyroidism. Turk J Nephrol. 2019;28(2):132-7. PMid:20352364 DOI: https://doi.org/10.5152/turkjnephrol.2019.3394

Bureo JC, Arévalo JC, Antón J, Adrados G, Jiménez Morales JL, Robles NR, et al. Prevalence of secondary hyperparathyroidism in patients with stage 3 and 4 chronic kidney disease seen in internal medicine. Endocrinol Nutr. 2015;62(7):300-5. https://doi.org/10.1016/j.endoen.2015.08.007 PMid:26138703 DOI: https://doi.org/10.1016/j.endoen.2015.08.007

Levin A, Bakris GL, Molitch M, Smulders M, Tian J, Williams LA, et al. Prevalence of abnormal serum Vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: Results of the study to evaluate early kidney disease. Kidney Int. 2007;71(1):31-8. https://doi.org/10.1038/sj.ki.5002009 PMid:17091124 DOI: https://doi.org/10.1038/sj.ki.5002009

Malawadi BN, Suma MN, Prashant V, Akila P, Anjalidevi BS, Manjunath S. Secondary hyperparathyroidism in all the stages of chronic kidney disease in Southern Indian population. Int J Pharm Pharm Sci. 2014;6(4):287-90.